Avalyn Pharma Inc. Common Stock - Asset Resilience Ratio
Avalyn Pharma Inc. Common Stock (AVLN) has an Asset Resilience Ratio of 20.74% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AVLN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Avalyn Pharma Inc. Common Stock's Asset Resilience Ratio has changed over time. See financial agility of Avalyn Pharma Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Avalyn Pharma Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Avalyn Pharma Inc. Common Stock asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $88.23 Million | 20.74% |
| Total Liquid Assets | $88.23 Million | 20.74% |
Asset Resilience Insights
- Good Liquidity Position: Avalyn Pharma Inc. Common Stock maintains a healthy 20.74% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Avalyn Pharma Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Avalyn Pharma Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Dyne Therapeutics Inc
NASDAQ:DYN |
Biotechnology | 20.28% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX |
Biotechnology | 0.00% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
Annual Asset Resilience Ratio for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Avalyn Pharma Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.79% | $86.04 Million | $148.88 Million | -11.81pp |
| 2024-12-31 | 69.60% | $86.67 Million | $124.52 Million | -- |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more